Xortx TherapeuticsXRTX
13F holders, Q3 2025 (September 30)6holders
2new positions
2sold out
1famous investor
$0.81avg. 13F price*
At the end of Q3 2025, 6 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, unchanged from Q2 2025. 2 opened new positions and 2 sold out. The largest holders were Citadel Advisors ($70K), XTX Topco Ltd ($11K) and Clearstead Advisors, LLC ($225). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $11K |
| Exits | 2 | $4K |
All 13F filers, Q2 2025 → Q3 2025: 61,679 shares bought and 25,295 shares sold, net +36,384 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Citadel Advisors | 0.00% | Add +124.4% | 86,326 | $70K |
| XTX Topco Ltd | 0.00% | New | 13,820 | $11K |
| Clearstead Advisors, LLC | 0.00% | No change | 277 | $225 |
| UBS Group AG | 0.00% | Reduce -98.9% | 234 | $190 |
| SBI Securities Co., Ltd. | 0.00% | New | 1 | $1 |
| Royal Bank of Canada | 0.00% | Reduce -46.0% | 358 | $0 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.